ArticleMolecular medicine reports2026
FOXJ3 drives mesenchymal stem cell osteogenic differentiation via the Wnt/β‑catenin pathway: A novel regulator implicated in osteoporosis.
Article in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- G protein-coupled receptor signaling in osteogenic bone mesenchymal stem/stromal cells.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis involves impaired osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). The present study identified the transcription factor forkhead box (FOXJ3) as a novel regulator of this process. During in vitro osteogenic differentiation of BMSCs, FOXJ3 expression progressively increased, and was positively correlated with osteogenic markers Runt‑related transcription factor 2 (RUNX2) and osteocalcin (OCN). Functional studies confirmed the essential role of FOXJ3: Small interfering RNA‑mediated knockdown markedly impaired differentiation, as evidenced by reduced alkaline phosphatase (ALP) activity, diminished mineralized nodule formation, and downregulation of RUNX2 and OCN. Conversely, lentivirus‑induced FOXJ3 overexpression enhanced these osteogenic markers and outcomes. Mechanistically, FOXJ3 knockdown suppressed active β‑catenin expression, indicating Wnt/β‑catenin pathway involvement. Crucially, the Wnt/β‑catenin agonist SB216763 rescued the inhibitory effects of FOXJ3 knockdown on ALP activity and mineralization. Conversely, the pro‑osteogenic effects of FOXJ3 overexpression were abrogated by the Wnt inhibitor XAV939. These findings establish FOXJ3 as a positive regulator of BMSC osteogenic differentiation acting primarily through the Wnt/β‑catenin pathway, presenting a novel potential therapeutic target for osteoporosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.